SgtrCypB Formulated with Freund’s Adjuvant Confers Protective Immunity Against S. globosa and Partial Cross-Protection Against S. schenckii Infections in Mice
Open Access
- 21 September 2026
- journal article
- research article
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (9) , 706
Abstract
Sporothrix globosa is the predominant cause of sporotrichosis in China, highlighting the need for effective vaccine strategies. Cyclophilins from pathogenic microorganisms have emerged as potential vaccine antigens. We previously generated a high-yield, high-purity recombinant truncated S. globosa cyclophilin B protein (SgtrCypB) retaining its functional domain. Here, BALB/c mice were immunized subcutaneously with SgtrCypB alone or formulated with Freund’s adjuvant to evaluate immunogenicity. Only the adjuvant-formulated vaccine induced a high antibody titer (1:51,200). Then, the infection-challenge experiments compared the SgtrCypB formulated with Freund’s adjuvant and PBS formulated with Freund’s adjuvant groups. Following challenge, SgtrCypB plus adjuvant reduced cutaneous lesion size (0.6 vs. 1.0 cm at week 1) without significantly affecting ulcer incidence. In systemic S. globosa infection, vaccination increased survival to 90% versus 40% in controls and reduced organ fungal burdens. Partial cross-protection was observed against S. schenckii, with 60% versus 20% survival and lower fungal burdens in the kidneys and lungs. Protection against C. albicans was minimal. These findings identify SgtrCypB as a promising protective antigen against S. globosa and S. schenckii and support further evaluation with clinically applicable adjuvants.Keywords
Funding Information
- National Natural Science Foundation of China (U24A20745)
- Guangzhou Municipal Science and Technology Bureau (2024B01J1191)
This publication has 70 references indexed in Scilit:
- The immune-stimulating particle adjuvant (ISPA) as a versatile adjuvant platform for recombinant vaccines against chronic Toxoplasma gondii infectionActa Tropica, 2026
- Engineered HSP90 ‐ MP65 Bivalent Fusion Antigen: A Novel Vaccine Candidate Against Invasive CandidiasisProteins: Structure, Function, and Bioinformatics, 2026
- An Outbreak of Sporotrichosis Associated With Tying CrabsJAMA Dermatology, 2025
- Immunity to fungi and vaccine considerationsCell Host & Microbe, 2024
- Research progress on emulsion vaccine adjuvantsHeliyon, 2024
- A Spotlight on Sporothrix and SporotrichosisMycopathologia, 2022
- The threat of emerging and re-emerging pathogenic Sporothrix speciesMycopathologia, 2020
- A cell wall protein-based vaccine candidate induce protective immune response against Sporothrix schenckii infectionImmunobiology, 2016
- Molecular cloning and characterization of a cyclophilin A homologue from Schistosoma japonicumParasitology Research, 2012
- Gamma Radiation Effects on Sporothrix schenckii Yeast CellsMycopathologia, 2011